Efficacy of Ketorolac 0.4% in Prostaglandin Suppression
Information source: Allergan
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Inflammation
Intervention: Ketorolac 0.4% (Drug); Lubricating Eye Drop (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Allergan Official(s) and/or principal investigator(s): Medical Director, Study Director, Affiliation: Allergan
Summary
A pilot study to evaluate the extent of PGE2 inhibition (mean aqueous values) by Ketorolac
0. 04% following peripheral iridotomy
Clinical Details
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science
Primary outcome: Mean Prostaglandin E2 (PGE2) Aqueous Humor Levels
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients scheduled to undergo phakic IOL implantation
Exclusion Criteria:
- History of intraocular surgery in the operative eye
Locations and Contacts
Houston, Texas, United States
Additional Information
Starting date: November 2008
Last updated: September 21, 2011
|